Women's International Pharmacy: Company Overview and Business Model

What Is Women's International Pharmacy?

Women's International Pharmacy is a specialty compounding pharmacy, not a telehealth clinic or prescribing service. Founded in 1985, it operates facilities in Madison, Wisconsin, and Youngtown, Arizona. The pharmacy fills custom hormone prescriptions written by a patient's own physician, nurse practitioner, or other licensed prescriber.

The core business model is straightforward: a clinician orders a specific formulation (dose, delivery route, base) that is not commercially available in that exact form, and WIP compounds and ships it to the patient. The pharmacy does not employ prescribers or provide diagnoses.

PCAB Accreditation and What It Means

WIP holds accreditation from the Pharmacy Compounding Accreditation Board (PCAB), a voluntary program administered by the National Association of Boards of Pharmacy (NABP). PCAB accreditation requires compliance with USP Chapter <795> (non-sterile) and <797> (sterile) standards, routine quality testing, and facility inspections.

PCAB status is meaningful. It distinguishes WIP from unaccredited compounders that have drawn FDA warning letters. Still, PCAB accreditation does not mean the compounded drug itself has passed FDA efficacy or safety review. The distinction matters clinically.

Regulatory Standing of Compounded Drugs

The FDA does not approve individual compounded preparations. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a pharmacy may compound a drug for a specific patient based on a valid prescription, provided it does not copy a commercially available product without clinical rationale [1]. This is the legal framework WIP operates under.

The FDA has flagged "essentially a copy" concerns with compounders that offer standard estradiol doses already available as FDA-approved patches or gels. Prescribers ordering from WIP should document the clinical reason a commercial product is inadequate for that specific patient.

What Does Women's International Pharmacy Compound?

WIP specializes in hormone preparations for women across the menopausal transition, though it also compounds androgens and adrenal hormones. The product range is broad and customizable by design.

Estrogen Formulations

WIP can prepare:

• Estradiol (E2) in cream, gel, troche, suppository, or capsule form
• Estriol (E3) in cream or troche form
• Bi-est and Tri-est (combined E2/E3 or E1/E2/E3 blends)

Estriol-only and Tri-est blends deserve a specific clinical note. Neither has FDA-approved status, and the evidence base for preferring them over estradiol alone is thin. The Endocrine Society's 2015 position statement states: "The evidence base supporting compounded hormone formulations is insufficient to conclude they are safe or effective" [2]. Bi-est and Tri-est combinations in particular lack randomized controlled trial data on endometrial safety.

Progesterone and Progestogens

WIP compounds micronized progesterone in bases and concentrations that differ from Prometrium (the FDA-approved oral micronized progesterone at 100 mg and 200 mg). Compounded progesterone topical creams remain a specific area of concern because transdermal absorption is variable and unpredictable. A 2005 study in Menopause (N=40) found that a compounded progesterone cream at commonly used doses did not produce serum levels sufficient to protect the endometrium in women using estrogen [3].

Testosterone and DHEA

Testosterone for women is not FDA-approved in the United States in any product, making this one of the few genuinely legitimate uses of compounding: the only way a US woman can access prescription testosterone is through a compounded preparation. WIP offers testosterone in cream and troche forms at low doses appropriate for women (typically 0.5 to 2 mg/day).

DHEA (dehydroepiandrosterone) compounded for vaginal use mirrors the active ingredient in Intrarosa (prasterone 6.5 mg), which is FDA-approved for dyspareunia. A compounded vaginal DHEA suppository may cost less than Intrarosa, though bioavailability differences between proprietary and compounded versions have not been formally studied in head-to-head trials.

Delivery Routes

Available delivery forms include oral capsules, sublingual troches, topical creams and gels, vaginal creams and suppositories, and transdermal preparations. Route selection affects both pharmacokinetics and risk profile. Oral estrogens increase sex hormone-binding globulin and, in some data, carry a modestly higher VTE risk compared to transdermal routes [4].

Is Women's International Pharmacy Legitimate?

Yes, WIP is a licensed, PCAB-accredited pharmacy with a four-decade operating history. It is not a gray-market or offshore operation. Whether its products are the right clinical choice for any individual patient is a separate question.

State Licensing and Inspections

WIP holds pharmacy licenses in all states where it ships and is subject to inspection by state boards of pharmacy. No active FDA warning letters or consent decrees appear on WIP's public record as of this writing (verify current status at accessdata.fda.gov). That track record compares favorably with the compounding pharmacies cited in the 2012 New England Compounding Center meningitis outbreak, which involved a non-PCAB, non-compliant facility.

The "Legitimate but Not Superior" Distinction

Legitimacy and clinical superiority are different concepts. The North American Menopause Society (NAMS) 2022 Hormone Therapy Position Statement notes: "FDA-approved hormone therapies are recommended when safe and effective products are commercially available" [5]. NAMS does not categorically oppose compounding but reserves it for situations where commercial products cannot meet clinical need, such as specific delivery routes, allergen avoidance, or doses not commercially available.

Prescribers should treat WIP as a tool for specific gaps, not a default first choice over FDA-approved bioidentical options like estradiol patches (Climara, Vivelle-Dot), estradiol gel (Divigel, EstroGel), or FDA-approved vaginal estradiol (Vagifem, Imvexxy).

Clinical Evidence for Compounded BHRT: What the Data Show

This section matters most for patients evaluating whether to use WIP's products over FDA-approved alternatives.

What "Bioidentical" Actually Means

The term "bioidentical" means the hormone molecule is chemically identical to the hormone produced endogenously. By that definition, FDA-approved estradiol patches are also bioidentical. The word is a marketing descriptor, not a regulatory or pharmacological category. WIP's website and many prescribers who refer patients to WIP use "bioidentical" to imply superiority, but no head-to-head RCT has demonstrated that WIP-compounded hormones produce better patient outcomes than FDA-approved bioidentical preparations.

Key Trial Data

The WHI (Women's Health Initiative) trials that raised safety concerns in 2002 used conjugated equine estrogens and medroxyprogesterone acetate, not bioidentical hormones. Those findings do not directly apply to transdermal estradiol plus micronized progesterone regimens [6].

The E3N cohort study (N=80,377 French women) found that combined estrogen plus progesterone, particularly with transdermal estradiol and micronized progesterone, was associated with a lower breast cancer risk than regimens using synthetic progestins [7]. This observation supports choosing micronized progesterone over medroxyprogesterone acetate, but it does not distinguish compounded from FDA-approved micronized progesterone (Prometrium).

The ELITE trial (N=643) showed that oral estradiol started within 6 years of menopause slowed carotid intima-media thickness progression vs. Placebo (P<0.008), supporting the timing hypothesis for cardiovascular benefit [8]. Again, the active drug was commercially available oral estradiol, not a custom compound.

Saliva Testing: A Specific Concern

Many practitioners who work with WIP use saliva hormone testing to monitor levels and adjust compounded doses. The Endocrine Society's Clinical Practice Guideline on menopausal hormone therapy states: "Salivary hormone testing should not be used to guide hormone dosing" [2]. Serum or 24-hour urine testing, interpreted within the clinical context, are the guideline-recommended monitoring approaches.

HealthRX Decision Framework: When Compounding Is Justified

Our medical team uses four criteria to determine whether a compounded preparation from a pharmacy like WIP is clinically warranted over an FDA-approved option:

1. No commercial equivalent exists at the required dose or route (testosterone for women is the clearest example).
2. Documented allergy or intolerance to an excipient in every FDA-approved formulation of the hormone.
3. Dose titration need that cannot be met by splitting or combining commercially available products.
4. Patient is already stable on a compounded regimen with documented serum levels in an appropriate range and no safety concerns.

If none of those four conditions apply, an FDA-approved bioidentical preparation is the preferred starting point.

How Much Does Women's International Pharmacy Cost?

WIP does not publish a public price list, because cost depends on the specific formulation, quantity, and shipping destination. Based on patient-reported data and prescriber accounts, typical ranges are:

| Formulation | Approximate monthly cost | |---|---| | Compounded estradiol cream (30 g) | $35, $65 | | Compounded Bi-est cream (30 g) | $40, $75 | | Compounded progesterone cream (30 g) | $30, $55 | | Compounded testosterone cream (30 g) | $45, $90 | | Compounded DHEA suppositories (30 ct) | $50, $110 | | Multiple-hormone combination | $80, $180+ |

Insurance coverage for compounded hormones is inconsistent. Most major commercial plans classify them as non-covered compounded drugs. FSA and HSA funds may apply if a valid prescription exists. Compare this to FDA-approved options: generic estradiol patches cost $15, $40/month under most plans, and Prometrium 200 mg generic runs approximately $20, $60/month.

The cost gap can be significant, especially when multiple hormones are compounded simultaneously. Patients should request an itemized quote from WIP before initiating therapy.

Women's International Pharmacy vs. Alternatives

Patients considering WIP typically have three other paths available.

FDA-Approved Bioidentical Products

These include estradiol transdermal patches (Climara 0.025 to 0.1 mg/day; Vivelle-Dot), estradiol gels (EstroGel 0.06%, Divigel 0.1%), estradiol vaginal options (Vagifem 10 mcg tablet, Imvexxy 4 to 10 mcg ring-free insert), and oral micronized progesterone (Prometrium 100/200 mg). These carry the full weight of FDA-reviewed clinical trial data and consistent quality manufacturing under cGMP standards.

For most newly diagnosed menopausal patients, this category is the first-line recommendation per NAMS 2022 [5].

Other Compounding Pharmacies

PCAB-accredited alternatives include Belmar Pharmacy, Help Pharmacy, and Stanton Optical Pharmacy (compounding division), among others. WIP's distinction is its long track record and exclusive focus on women's hormones. Patients who prefer a pharmacy with deep specialty focus may find that narrowness reassuring.

Telehealth Platforms with In-House Compounding

Platforms like Midi Health, Evernow, Alloy, and Winona pair prescribers with compounding pharmacies. Some use PCAB-accredited compounders; some use in-house pharmacy operations. The advantage is integrated prescribing and monitoring. The disadvantage is less transparency about which compounding facility fulfills the prescription.

Patients who currently lack a hormone-knowledgeable prescriber may find a telehealth platform more accessible than sourcing both a prescriber and WIP independently.

How to Use Women's International Pharmacy Safely

Using WIP requires an active, valid prescription from a licensed practitioner. The workflow is:

1. Establish care with a prescriber trained in hormone therapy (gynecologist, endocrinologist, or hormone-trained internist/NP).
2. Baseline labs: Obtain serum FSH, estradiol, total and free testosterone, SHBG, and a CBC/CMP before initiating any hormone. Thyroid function (TSH, free T4) is prudent given symptom overlap.
3. Prescriber contacts WIP: The prescriber faxes or electronically submits a prescription specifying the exact compound, concentration, base, and quantity.
4. WIP ships directly: Most orders ship within 3 to 5 business days.
5. Follow-up labs at 6 to 12 weeks: Recheck serum levels. The Endocrine Society recommends serum testing, not saliva, for monitoring [2].
6. Annual review: Reassess benefit and risk annually per NAMS guidance. The lowest effective dose for the shortest necessary duration remains the guiding principle for all hormone therapy [5].

Patients should not adjust compounded hormone doses based on symptom sensation alone. Serum confirmation is essential before any dose change, because compounded preparations can have variable batch potency even from accredited pharmacies.

Patient Perspective: What Reviews Reveal

Patient reviews of WIP (collected across Google, Yelp, and health forums) consistently praise the pharmacy's customer service, educational materials, and willingness to field clinical questions from patients and prescribers. Negative reviews cite cost, inconsistent insurance coverage, and shipping delays.

A recurring theme in reviews is high satisfaction with the prescriber relationship rather than with WIP specifically. WIP's educational content (newsletters, practitioner guides) appears to be a meaningful differentiator: practitioners who refer patients to WIP often do so partly because of WIP's educational support resources. That is a legitimate business-model advantage, though it does not change the clinical evidence profile of the products themselves.

Key Safety Considerations

Compounded BHRT carries the same class-level risks as FDA-approved hormone therapy: increased VTE risk (lower with transdermal vs. Oral routes [4]), potential endometrial hyperplasia without adequate progestogen opposition in women with a uterus, and the ongoing discussion about breast cancer risk that varies by hormone type, duration, and timing of initiation.

Specific compounding risks include:

• Potency variability: USP allows a 90 to 110% potency range for compounded preparations, but real-world variability can exceed this.
• Sterility for non-sterile preparations: Topical creams are non-sterile by definition; contamination risk exists with poor handling.
• Unproven delivery vehicles: Some exotic bases used in compounding (liposomal, lipoderm) have no pharmacokinetic validation data in published literature.

The FDA's 2020 guidance on compounded hormones specifically warns against preparations that deviate from established bioavailability data without clinical justification [1].